IMU Secures $53 Million in Latest Series A Funding Round

IMU secured $53 million in its latest Series A, adding another data point to the Healthcare & Life Sciences funding market.

IMU Raises $53 million in Funding

IMU is a Digital Health company focused on decode the immune system at scale.

Investors Behind the Funding

The round was backed by IQ Capital. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

IMU operates in Healthcare & Life Sciences. IMU's Series A round shows investors are still backing digital health platforms with real scale narratives. At $53M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

decode the immune system at scale

Looking Ahead

IMU closes $53m Series A to decode the immune system at scale

Source reference: original announcement/article.